VANCOUVER, British Columbia, March 14, 2018 (GLOBE NEWSWIRE) -- RavenQuest BioMed Inc. (the “Company” or
“RavenQuest”) – (CSE:RQB) is pleased to announce it has appointed Dr. Simerjeet Kaur, PhD, to lead Scientific Research &
Development.
Dr. Kaur will lead the Company’s R&D and scientific training efforts, specifically relating to the
development of new high yielding, stress resistant Cannabis varieties for medicinal as well as recreational purposes.
“Dr. Kaur is a leader in her field. RavenQuest is thrilled to bring an accomplished and highly respected
plant breeder and geneticist onboard. In assembling our senior team members, our focus has been upon attracting thought
leaders with proven results in their respective fields. The addition of Dr. Kaur is yet another example of this. The
addition of Dr. Kaur, combined with our McGill University research partnership, positions RavenQuest to lead the cannabis industry
with stable, high yielding cannabis expression based in science,” stated George Robinson, CEO of RavenQuest. “As our industry
matures, it’s important to deliver a consistent, repeatable experience for our end users while maximizing plant yields that keep
margins healthy for shareholders. To that end, Dr. Kaur’s expertise is instrumental to RavenQuest as we continue to build a
very unique cannabis company.”
Dr. Kaur is an expert in plant breeding, genetics, plant physiology and biochemistry. She obtained her
Doctor of Philosophy in plant breeding and genetics from McGill University, and Master’s Degree in plant physiology and
biochemistry from Punjab Agricultural University. During her PhD, she was a visiting scholar at Washington State University
(USA) to work with experts in the field of molecular breeding and varietal development.
Her research led to significant contributions in varietal development, novel gene identification and gene
function prediction. Through association mapping, she discovered novel genes that can be used as markers for breeding
programmes to improve the ability of plants to cope with biotic and abiotic stress resistance. Dr. Kaur has published in
several peer reviewed journals on crop genetics, breeding and physiology. Her breeding program led to the development of a
high yielding, stable rice variety that is currently being used in commercial rice production. She also has delivered
lectures on genomics, molecular biology and plant breeding.
About RavenQuest BioMed Inc.
RavenQuest BioMed Inc. is a diversified publicly traded cannabis company with divisions focused upon cannabis
production, management services and consulting, and specialized research and development.
On Behalf of the Board of Directors of
RAVENQUEST BIOMED INC.
"George Robinson"
Chief Executive Officer
For further information, please contact:
Mathieu McDonald, Corporate Communications 604-484-1230
Cautionary Note Regarding Forward-Looking Statements
All statements in this press release, other than statements of historical fact, are "forward-looking
information" with respect to the Company within the meaning of applicable securities laws. The Company provides
forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and
readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is
subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that
expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct
and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited
to those identified and reported in the Company’s public filings under the Company’s SEDAR profile at www.sedar.com. Although the
Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from
those described in forward-looking information, there may be other factors that cause actions, events or results not to be as
anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and
future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation
to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless
required by law.
